论文部分内容阅读
目的探讨熊去氧胆酸在肝胆相关性疾病患者中的应用效果。方法 106例肝胆相关性疾病患者中有45例慢性胆囊炎患者,分为A组(21例)给予熊去氧胆酸,B组(24例)给予消炎利胆片;31例胆汁反流性食管炎患者,分为A组(15例)熊去氧胆酸联合奥美拉唑肠溶片,B组(16例)单用奥美拉唑肠溶片治疗;19例肝内胆汁淤积症患者,分为A组(10例)单用熊去氧胆酸,B组(9例)用甘草酸铵注射液联合其他抗过敏药治疗,2例妊娠期肝内胆汁淤积症产后患者1例用熊去氧胆酸治疗8年,另外1例未做任何治疗;1例肝囊肿患者用熊去氧胆酸联合复方阿嗪咪特肠溶片治疗;10例脂肪肝患者,分为A组(5例)给予熊去氧胆酸,B组(5例)给予辛伐他汀片治疗。观察治疗相应时间后患者症状消失及缓解情况和实验室检查及B超复查情况。结果治疗后慢性胆囊炎有效率A组(81%)高于B组(54%);胆汁反流性食管炎有效率A组(87%)高于B组(0);肝内胆汁淤积症有效率A组(80%)高于B组(11%);1例妊娠期肝内胆汁淤积症患者产后用熊去氧胆酸治疗亦取得明显疗效;脂肪肝有效率A组(100%)高于B组(40%)。各组比较差异均具有统计学意义(P<0.05)。结论熊去氧胆酸或联合他药在治疗肝胆相关性疾病中疗效显著,不良反应少,值得推广。
Objective To investigate the effect of ursodeoxycholic acid in hepatobiliary-related diseases. Methods A total of 45 patients with chronic cholecystitis in 106 patients with hepatobiliary-related diseases were divided into group A (21 cases) and ursodeoxycholic acid (group B) (24 cases) Esophagitis patients were divided into group A (15 cases) ursodeoxycholic acid combined omeprazole enteric-coated tablets, B group (16 cases) single-use omeprazole enteric-coated tablets treatment; 19 cases of intrahepatic cholestasis Patients were divided into group A (n = 10) with ursodeoxycholic acid alone, group B (n = 9) with glycyrrhizinate and other antiallergic drugs, and 1 patient with intrahepatic cholestasis of pregnancy Ursodeoxycholic acid treatment for 8 years, the other 1 without any treatment; 1 case of liver cyst with ursodeoxycholic acid combined with compound Alzamine tablets enteric-coated tablets; 10 cases of fatty liver patients were divided into A group (5 cases) were given ursodeoxycholic acid, B group (5 cases) given simvastatin tablets treatment. Observe the treatment of the patient’s symptoms disappeared and the corresponding situation and the time of laboratory tests and B-review of the situation. Results The effective rate of chronic cholecystitis in group A (81%) was higher than that in group B (54%). The effective rate of bile reflux esophagitis was 87% in group A and group B (0). The intrahepatic cholestasis Group A (80%) was more effective than Group B (11%). One patient with intrahepatic cholestasis of pregnancy also achieved significant effect after ursodeoxycholic acid treatment. The effective rate of fatty liver group A was 100% Higher than the B group (40%). The differences between groups were statistically significant (P <0.05). Conclusion Ursodeoxycholic acid or combined with other drugs in the treatment of hepatobiliary disease significant effect, less adverse reactions, it is worth promoting.